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Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed 
world. EOC metastasis is unique since malignant cells detach directly from the primary tumor 
site into the abdominal fluid and form multicellular aggregates, called spheroids, that possess 
enhanced survival mechanisms while in suspension. As such, altered cell adhesion properties are 
paramount to EOC metastasis with cell detachment from the primary tumor, dissemination as 
spheroids, and reattachment to peritoneal surfaces for secondary tumor formation. that play a 
crucial role in cell-cell and cell-extracellular matrix interactions, having implications in multiple 
steps of cancer progression. We previously showed that the CRISPR-ablation of LKB1 or its 
downstream effector NUAK1 resulted in spheroid disaggregation in vitro and is required for 
efficient EOC metastasis in mouse tumor cell xenografts. Global gene expression analysis 
demonstrated a coordinated reduction in 5-integrin (encoded by ITGβ5 gene). Integrins are a 
family of cell-adhesion receptors required to mediate cellular interactions with the extracellular 
matrix (ECM) and promote tumorigenesis in various malignancies; however, the role of 5-
integrin in EOC is unknown. Using publicly-available datasets and western blot analysis, we 
identified relatively high 5 integrin expression in established and patient ascites-derived EOC 
cell lines. siRNA-mediated knockdown of ITGβ5 reduced EOC cell adhesion, impacted adherent 
cell and spheroid viability. We identified that 5 integrin is required for efficient spheroid 
reattachment and subsequent cell spreading. When evaluating the interaction of 5 integrin with 
ECM ligands, results indicate that 5 integrin and its association with vitronectin may play a role 
in spheroid reattachment.  
 




Summary for lay Audience 
 
Epithelial ovarian cancer is one of the most lethal gynaecological cancers in the developed world 
and most individuals are diagnosed at advanced stages. When ovarian cancer cells spread, a 
process called metastasis, the cancer cells try to survive starvation-like conditions by forming 
cell clusters called spheroids. During this time, ovarian cancer cells change their cell adhesion 
properties to allow them to survive and form more tumours. Our laboratory discovered that a 
molecule called “Liver Kinase B1” (LKB1) and its downstream target, NUAK1, enables ovarian 
cancer cells to survive these stressful conditions using different strategies to generate energy. 
The loss of these two molecules leads to a decrease in a cell adhesion molecule called β5 
integrin. My work focuses on taking a closer look at the change in cell adhesion properties in 
ovarian cancer because they are a critical aspect of metastasis. Currently, I am using different 
functional assessments to determine the role of β5 integrin in cell adhesion and spheroid 
formation. Understanding how ovarian cancer cells alter their cell adhesion to allow for 
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1.1. Epithelial ovarian cancer 
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed 
world[1]. Most women are diagnosed with advanced-stage disease with a 5-year survival rate of 
less than 29%, since 80% of these cases present initially with metastasis[1], [2]. The delay in 
diagnosis can be attributed to the wide range of non-specific symptoms like abdominal fullness, 
vaginal bleeding  and urinary symptoms thereby leading to a more advanced-stage before clinical 
assessment[3]. Factors for increased risk include early age of menarche, and benign gynecological 
conditions such as endometriosis, polycystic ovary and pelvic inflammatory disease, whereas oral 
contraceptive use and tubal ligation can decrease risk for EOC[1].  The current treatment plan for 
patients with EOC in which tumors have spread beyond the ovaries is maximal surgical 
cytoreduction with adjuvant chemotherapy of combined carboplatin and paclitaxel[1]. However, 
75% of patients will have disease reoccurrence, oftentimes acquiring chemotherapy resistance, 
ultimately leading to a dire prognosis[1], [3]. 
EOC encompasses a heterogenous group of malignant tumors that differ in prognosis, 
molecular pathology, and etiology. According to the World Health Organization (WHO), EOC can 
be classified into seven histological subtypes: high-grade and low-grade serous, mucinous, 
endometrioid, clear cell, Brenner, seromucinous and undifferentiated carcinomas[4]. These 
histological subtypes can be organized into two major EOC groups where Type I consists of lower 
grade, slow-proliferating carcinomas within serous, endometrioid, mucinous and clear cell 
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histological subtypes that likely arise from benign ovarian lesions[4], [5] . Whereas Type II tumors 
are typified as being more aggressive disease derived from secretory fallopian tube epithelium, 
and present histologically as high-grade serous, mixed epithelial or undifferentiated 
carcinomas[5], [6]. High-grade serous ovarian cancer (HGSOC) represents 75% of all cases and 
is characterized by the near universal presence of TP53 tumor suppressor gene mutations, 
commonly as observed as missense gain-of-function alterations, although deletions and nonsense 
loss-of-function mutations have been identified, too[7], [8] . This genetic alteration arises within 
an early tumor precursor cell of the distal fallopian tube, called serous tubal intraepithelial 
carcinoma (STIC) lesion; protein-stabilizing TP53 missense mutations promote secretory 
epithelial cell survival and cell-cell aggregation under anchorage independent growth 
conditions[8]. HGSOC is associated with lower prevalent but recurrent somatic mutations in NF1, 
BRCA1, BRCA2, RB1 and CDK12 totalling 5-8% of tumors[1], [8].   
Furthermore, advanced EOC is characterized by ascites fluid accumulation within the 
peritoneal cavity[5]. The impairment of lymphatic drainage and increased secretion of vascular 
endothelial growth factor (VEGF) leads to enhanced vascular permeability[5]. The unique 
microenvironment within malignant EOC ascites consists of a variety of non-tumor cell types, 
such as fibroblasts, mesothelial cells, immune cells and endothelial cells, as well as acellular 
components, such as soluble extracellular matrix (ECM), matrix-degrading enzymes, cytokines 
and growth factors[9].  
1.2. Extracellular Matrix interactions in EOC 
The ECM is an integral and dynamic non-cellular component within all tissues and functions 
to support cells and maintain tissue homeostasis[9]–[11]. Normal ovarian ECM is composed of a 
highly-ordered arrangement of collagen fibers and proteoglycans, such as decorin and versican, to 
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provide structural integrity, and maintain interstitial pressure and hydration to tissue[9]–[11]. 
However, ECM stiffness is commonly increased in EOC tumors through the activation of stromal 
fibroblasts and collagen remodeling into thick fibrils in random orientation, which can combine to 
increase tumorigenesis, cancer invasion and migration[10]–[12]. For example, decorin loss and 
upregulation of versican, fibronectin, tenascin-C, and tenascin-X are associated with poor 
prognosis and overall survival in EOC[9], [12]. The binding of various ECM ligands to integrins, 
which are glycoprotein receptors at the cell surface to promote adhesion, regulate complex 
signaling events alone or in combination with growth factor receptors[13], [14].  
The interactions between the tumor cells and ECM within the tumor microenvironment are 
crucial since their dysregulation has been implicated in EOC progression[9], [13]. Therefore, 
integrin-mediated interactions and function within the tumor micro-environment represents a 
potential unique therapeutic strategy in EOC. In this review, we discuss the contributions of 
integrin-mediated cell adhesion in the critical steps during intraperitoneal metastatic cascade of 
EOC pathogenesis, including spheroid formation, epithelial-mesenchymal plasticity, and 
mesothelial attachment of secondary tumors.   
 
1.3. Integrin signalling  
The integrins comprise a superfamily of cell adhesion receptors that recognize ECM and cell-
surface ligands[15]. There are 18 α-subunits and 8 β-subunits that assemble to create 24 
functionally distinct transmembrane heterodimers. Integrins are grouped according to their ligand-
binding specificity: collagen-binding integrins (α1β1, α2β1, α10β1, and α11β1), laminin-binding 
integrins (α3β1, α6β1, α7β1, and α6β4), leukocyte-integrins (α4β1, α9β1, α4β7, αEβ7,αLβ2, αMβ2, αXβ2, 
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and αDβ2) and arginine-glycine-aspartate (RGD)-recognizing integrins (α5β1, α8β1, αVβ1, αVβ3, 
αVβ5, αVβ6,  αVβ8, and αIIbβ3)[15] (Figure 1.1). 
These receptor complexes have no enzymatic activity but instead activate bidirectional 
signaling pathways[13], [15]. The affinity of integrin receptors for ECM components and other 
ligands is tightly regulated by inside-out signaling[15].  Integrin receptors maintain α and β subunit 
cytoplasmic tail association during their inactive stage, and cytoplasmic signals from associated 
G-protein coupled receptors lead integrin β subunit phosphorylation within its cytoplasmic domain 
for receptor activation[15], [16]. The integrin binding of cytoskeletal proteins such as talin, 
vinculin and ERM (ezrin, radixin, and moesin) acts to regulate actin microfilaments of the 
cytoskeleton[15], [16]. In contrast, outside-in signaling occurs through the clustering of integrin 
receptors at the plasma membrane where ECM ligation transduces signals intracellularly[15], [17]. 
Natural extracellular ligands include several components of the ECM such as collagen, laminin, 
fibronectin and vitronectin[13], [15]. Extracellular ligand binding induces conformational changes 
in the integrin receptor to allow intracellular tails of the β subunit to engage with intracellular 
signaling molecules including focal adhesion kinase (FAK), small GTPases Rho and Ras, and 
adaptors, such as Cas/Crk and paxillin[17]. These activated integrin-ECM interactions lead to the 
formation of dynamic adhesion structures as small extensions from the plasma membrane called 
podosomes[15], [16], [18] . After ECM ligation, integrins acting alone or in complex with growth 
factors present in the local microenvironment can regulate diverse tumor cell functions, such as 







Integrins are a superfamily of cell adhesion receptors that recognize ECM and cell-surface ligand. They consist of 18 
α-subunits and 8 β-subunits that assemble to create 24 functionally distinct transmembrane heterodimers. (a) Integrins 
are grouped according to their ligand-binding specificity: arginine-glycine-aspartate (RGD)-recognizing integrins, 
laminin-binding integrins, collagen-binding integrins and leukocyte-integrins. (b) Integrins take part in bidirectional 
signaling once the integrins move from a bent configuration to an active form. During inside-out signaling, G-protein 
coupled receptors lead to integrin β subunit phosphorylation within the cytoplasmic domain for receptor activation. 
The integrin binding of cytoskeletal proteins such as talin, vinculin and ERM (ezrin, radixin, and moesin) acts to 
regulate actin microfilaments of the cytoskeleton. Outside-in signaling occurs through the clustering of integrin 
receptors at the plasma membrane where ECM ligation transduces signals intracellularly. ECM binding with ligands 
such as collagen, laminin and fibronectin induces conformational changes in the integrin receptor to allow intracellular 
tails of the β subunit to engage with intracellular signaling molecules including focal adhesion kinase (FAK), small 
GTPases Rho and Ras, and adaptors, such as Cas/Crk and paxillin. Integrin acting alone or in complex with growth 
factors present in the local microenvironment can regulate diverse tumor cell functions, such as migration, invasion, 
adhesion and proliferation through the activation of various signaling pathways. [created via biorender.com] 
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1.4. Implications of integrin function in EOC metastasis 
The primary site of origin for HGSOC is the secretory epithelial cells of the distal fallopian tube 
from precursor STIC lesions[7], [19]. After TP53 mutations occur, it is postulated that cells within 
precursor lesions can be further stimulated by local inflammatory cytokines, growth factors and 
hormones, such as transforming growth factor-beta (TGF-β) and activin A present in follicular 
fluid that can stimulate migration of STIC cells to the ovary[20]–[22]. The movement of STIC 
lesions to the rich microenvironment provided by the ovary is a critical step in the transition of 
STIC lesions to HGSOC by attaching, invading and establishing a primary tumor[1], [23]–[25]. 
This model has been supported by studies in which ovariectomies performed in mice harboring 
precursor lesions results in reduced tumor formation and intraperitoneal metastasis, emphasizing 
the importance of the ovarian microenvironment for complete malignant progression[23], [26].  
Unlike hematogenous routes involving intravasation and extravasation where cancer cells 
must penetrate multiple barriers, intraperitoneal dissemination is a common form of EOC 
metastasis, and is also observed less frequently in colorectal, gastric and pancreatic cancers[5], 
[27], [28]. Despite the more passive nature of intraperitoneal dissemination, it leads to rapid 
disease progression, frequent relapse, complications like bowel obstruction, and overall poor 
prognosis[5], [6]. During advanced-stage EOC, metastatic cancer cells impair lymphatic drainage 
and secrete vascular endothelial growth factor (VEGF) that enhances vascular permeability and 
ascites fluid accumulation in the peritoneal cavity[5], [29]. Ascites fluid often contains EOC cells, 
as well as a highly heterogeneous mix of other cellular and acellular components[5], [9]. Direct 
spread of EOC tumor cells into the peritoneal cavity is due to enhanced anchorage-independent 
tumor cell survival that may be supported by altered cell-cell and cell-ECM functions of various 
integrins. 
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1.4.1. Integrins in EOC spheroids 
EOC cells that are bound for metastatic dissemination must first detach from the primary tumor 
site. Proteolytic activity by membrane type 1 matrix metalloproteinase (MT1-MMP, or MMP14) 
is required in part for the initial detachment of EOC cells from the primary ovarian tumor by 
cleaving α3 integrin on cancer cells and contributing to decreased cell adhesion[30]. Detached EOC 
cells survive in hypoxic and anchorage-independent conditions by forming heterogenous 
multicellular structures known as spheroids thereby avoiding anoikis, which is a specific form of 
apoptosis triggered by the lack of attachment to other cells or ECM[5], [31], [32]. Spheroids further 
complicate the disease by exhibiting decreased cell proliferation by accumulating in the G0/G1 
phase of the cell cycle and becoming resistant to chemotherapeutic agents, such as paclitaxel and 
cisplatin[33], [34]. It is important to appreciate, however, that not all cells within spheroids may 
have the same properties. For example, spheroids can move in a coordinated fashion, a process 
called collective migration. This is driven by outer “leader” cells that direct migration and enable 
the invasion of basement membrane, then “follower cells” that mediate actomyosin contraction 
allowing for cellular movement[35], [36].  
The first step of spheroid formation consists of cell-cell interactions either directly or through 
ECM bridges. The abundance of integrins available to cells within these multicellular aggregates 
may provide a major contribution to spheroid formation and pro-survival signaling[37]. Doberstein 
et al. demonstrated that the loss of L1 cell adhesion molecule (L1CAM) reduced the capacity for 
OVCAR8 cells to form spheroids, ultimately leading to cell death[26]. Alternatively, L1CAM 
overexpression led to increased spheroid formation in OVCAR8 cells as well as multiple 
immortalized human fallopian tube epithelial cell lines[26]. L1CAM expression promotes the 
upregulation of fibronectin and integrin subunits α5 and β1, which together promote cell 
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aggregation into spheroids yet detachment from the primary tumor and tumorigenesis[26]. 
Fibronectin is abundant within the ascites and plays a critical role in spheroid integrity[38], [39] 
by interacting with its canonical integrin receptor α5β1[40], [41]. For example, OVCAR5 spheroids 
co-express of α5β1 integrin and fibronectin on the their surface[41]. The functional inhibition of β1 
integrin using an inhibitory antibody results in the disruption of EOC spheroids, whereas β1 
integrin clustering and fibronectin activate α5β1 heterodimer assembly to promote spheroid 
formation[41].  
Spheroid compaction into dense aggregates is critical for tumorigenesis and related to their 
actomyosin contractile capacity mediated by integrins and cadherins[39], [42]. A positive 
correlation may exist between compact spheroid formation and tumorigenic capacity, as well as 
enhanced invasive capacity in EOC[42]. Sodek et al. demonstrated that β1 integrin activation using 
an activating antibody 12G10 and ectopic β1 integrin upregulation enhanced more compact cell 
aggregation using SKOV3 and OVCAR3 cells, two EOC cell lines that typically form less compact 
spheroids[42]. Conversely, treating compact HEY cells spheroids with a β1-integrin blocking 
antibody MAB13 led to spheroid disaggregation[42]. Casey and colleagues also demonstrated that 
treating OVCAR5 cells with a β1-integrin blocking antibody inhibits spheroid formation, while 
addition of exogenous fibronectin promoted EOC spheroid formation[41]. Similarly, laminin 
interactions with α6β1 integrins, and collagen with α2β1-integrins, mediate spheroid formation[41], 
[43]. In contrast, spheroid formation can be enhanced in the presence of antibodies targeting α2, 
α4, α6 or αvβ3  integrins implicating these integrins may negatively regulate spheroid formation[41].  
Kellouche and colleagues identified αv integrin and vitronectin colocalization within 
multicellular aggregates at intercellular sites suggesting a contribution in cell-cell interactions[44]. 
They demonstrated through the use of anti-vitronectin, anti-αv integrin, or the cyclic peptide 
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cRGDfV, blocked initial formation of IGROV1 spheroids[44]. The blockade of αv integrins 
decreased integrin-linked kinase (ILK) activity resulting in reduced Akt phosphorylation and 
increased cell cycle inhibitor p27kip1 expression[45]. αv integrin can directly regulate ILK activity 
since anti-αv integrin inhibits ILK activity whereas ectopic ILK overexpression rescues the 
inhibitory effect of αv integrin blockade[45]. Anchorage-independent growth of IGROV1 cells 
leads to a significant decrease in ERK1/2 phosphorylation compared to adherent cells and 
inhibition of ERK1/2 activation with MEK1/2 inhibitor U0126 in IGROV1 spheroids led to a 
decrease in the number of viable cells and increase in PARP cleavage and caspase-3 activity[46]. 
Carduner et al. show that increased anoikis in IGROV1 spheroids due to αv-integrin silencing is 
associated with decreased ERK1/2 activation. This suggests that αv-integrin promotes spheroid 
cell survival by inducing ERK-dependent pathways[46]. This association has also been 
demonstrated in an anoikis-resistant population of human intestinal carcinoma cells due to αvβ3 
integrin expression[47].  
Cancer stem-like cells (CSC) may play a role in EOC spheroid formation. Exogenous CD90 
decreased SKOV3 spheroid formation and promoted apoptosis as seen by increased cleaved poly 
(ADP-ribose) polymerase expression[48]. Ectopic CD90 expression led to decreased expression 
of CSC markers CD133 and CD24, and promoted mTOR phosphorylation as well as its 
downstream target AMPK[48]. However, β3-integrin silencing increased anchorage-independent 
growth and CD133 marker expression. CD90 is associated with αvβ3 integrin through its regulation 
of signal transduction in astrocytes and neuronal cells[49]. Taken together, this suggests negative 
regulatory role of CD90 together with β3-integrin signaling in the context of CSCs and the EOC 
spheroid phenotype.  
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Spheroids present in malignant ascites can interact with other cell types to affect their 
phenotype. For example, an analysis of cell components in spheroids isolated from the ascites of 
128 patients with stage III ovarian cancer showed the presence of macrophages in all 
spheroids[50]. The number of macrophages present with spheroids compared to primary tumors 
was substantially higher and positively correlated with proliferation in spheroids and negatively 
with patient prognosis[50]. Robinson-Smith et al. demonstrated spheroid implantation in a mouse 
model of EOC increased due to inflammation, whereas the loss of peritoneal macrophages reduced 
metastatic potential, supporting the role of tumor-associated macrophages (TAMs) in EOC[51]. In 
fact, Yin et al. discovered that EOC spheroids express ICAM1, a ligand that binds leukocyte-
associated integrin subunits αM  and αX. Blockade of this interaction between EOC cells and TAMs 
diminished spheroid formation in mouse and human in vitro spheroid coculture models[50] TAMs 
are a source of epidermal growth factor (EGF), and EGF signaling is critical for EOC cell 
proliferation to increase VEGF-C and enhance integrin-ICAM1 expression, spheroid formation 
and migration[50].   
 
1.4.2. Integrins in epithelial-mesenchymal transition and EOC cell migration 
Cancer cells destined for dissemination co-express epithelial and mesenchymal markers, 
commonly referred to as epithelial-mesenchymal transition (EMT), allowing for a cadherin 
switch[36], [52]. EMT allows ovarian cancer cells to loosen intercellular adhesions between cells 
contributing to the transition of cells from a primary tumor to shed as single cells or spheroids into 
the ascites[5], [39]. During this EMT process, cancer cells gain a more invasive properties, survive 
in hypoxic conditions, and spread through the abdominal cavity by the peritoneal fluid flow[53]. 
The decrease in cell-cell adhesion and detachment of EOC cells from the primary tumor into the 
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peritoneal cavity is mediated through the integrin-mediated upregulation of matrix 
metalloproteinases (MMPs) and activation of EMT[36]. Clustering of collagen-binding integrins  
α2β1and α3β1on EOC cells leads to the induction of MMP9, which is capable of E-cadherin 
ectodomain cleavage and cell-cell adhesion loosening in an Src kinase-dependent manner[54]. E-
cadherin loss leads to transcriptional upregulation of fibronectin receptor α5β1 integrin, which is 
essential when spheroids initiate adhesion at a secondary site[55]. Decreased E-cadherin is also 
accompanied by reductions in occludins, claudins, epithelial cell adhesion molecule (EpCAM), 
α6β4 integrin and cytokines, all of which act to stabilize tight cell-cell contacts via 
desmosomes[22]. In a reciprocal fashion, there are increases in vimentin, fibronectin, N-cadherin, 
β1 and β3 integrins and matrix metalloproteinases[22]. Forced downregulation of E-cadherin in 
EOC cells increases α5 integrin expression through focal adhesion kinase (FAK) and ERK1 
activities leading to enhanced cell adhesion to fibronectin[56]. As expected, these EMT-like 
changes due to E-cadherin loss promote EOC cell invasive properties required for metastasis[53]. 
TGF- signaling is widely-recognized as one of the most important pathways required to 
promote EMT in human cancers. We have demonstrated that TGF-β activity is induced during 
ascites-derived EOC spheroid formation as indicated by increased mesenchymal marker 
transcripts, whereas TGF-β signalling inhibition dramatically reduces EMT properties and cell-
cell cohesion within spheroids[57]. Bianchi et al. have shown that β integrin subunits associated 
with αv integrin are upregulated during TGF-β induced EMT in breast carcinoma, and specific 
integrin β5 downregulation blocked TGF-β induced EMT[58]. Similarly, αvβ8 integrin mediates 
latent TGF-β activation and resultant EMT in various cancers contributing to cell migration and 
growth[59].  
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The ascites microenvironment may play a critical role in promoting a partial shift towards a 
mesenchymal phenotype in EOC cells[46]. When cultured EOC cells are exposed to ascites, αv 
integrin localization moves from focal contact structures to intracellular perinuclear vesicles in 
IGROV1 cells[46]. In a pulse-chase experiment, Carduner et al. showed IGROV1 cells exposed 
to ascites led to centripetal movement of αv integrin, whereas they remain localized to focal 
contacts in standard culture medium[46]. Furthermore, the αv integrin cyclic antagonist cRGDfc 
peptide inhibited multicellular aggregate formation by 40% compared to a non-targeting control 
peptide[46]. Although these studies suggest that αv-integrin and TGF-β work in concert to control 
EMT, cell adhesion and migration, a broader role of αv integrin complexes in EOC pathogenesis 
remains unclear and further investigation is required.  
When establishing secondary tumors, spheroids attach to the mesothelium lining through the 
interactions between spheroids and surface receptors on the mesothelial layer[22], [60]. At this 
point, spheroid cells induce expression of several integrins that prime the spheroids for attachment 
to the mesothelium and underlying ECM proteins[22], [41], [61]. For example, interaction between 
spheroid cells expressing α5β1  integrin receptor and the mesothelium containing fibronectin matrix 
is essential for spheroid adhesion[41]. Although Cannistra et al. showed that neutralizing 
antibodies against α5β1 and αvβ3 integrins did not affect the binding of EOC cells to the 
mesothelium, additional studies by this group and others have shown a partial block in adhesion 
when inhibitory β1  integrin antibody was administered[41], [62], [63]. Similarly, inhibition of α3, 
α6 and β1 integrin subunits decrease invasiveness and collagen-binding of spheroids[36]. As the 
major receptors for ECM proteins, integrins pose as critical regulators of cancer cell adhesion and 
invasion at a secondary site.    
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1.4.3. Integrin-mediated mesothelial attachment and migration 
The final step of EOC metastasis occurs when spheroids alter adhesion between tumor cells, 
penetrate mesothelial surfaces, and degrade the ECM within the basement membrane underlying 
the peritoneum, omentum and abdominal organs[64]. An early step in this process is the integrin-
mediated binding of EOC cells to mesothelial cells and exposed ECM[65]. Kaur et al. 
demonstrated that β3 integrin expression correlates with increased EOC cell adhesion in vitro and 
adhesion to mesothelium and mouse omentum in vivo[65]. However, they also showed that αvβ3 
overexpressing cells inhibited cell Matrigel invasion, and β3 integrin blockade resulted in enhanced 
invasion in CAOV3 and MONTY1 cells[65]. These latter results were recapitulated in vivo where 
αvβ3 overexpressing cells displayed a 35% decrease in intra-abdominal metastases and 53% 
decrease in tumor weight compared to controls[65]. These results highlight the potential 
mechanistic differences involving integrins between EOC cell adhesion, invasion, and successful 
secondary tumor formation.  
Integrins function in both cell-cell adhesion and binding to basement membrane and ligand 
components[64]. α2 and β1 integrin subunits contribute to EOC cell adhesion via collagen I 
facilitating peritoneal attachment and invasion into the mesothelial monolayers[66]. Studies have 
consistently shown that inhibition of collagen-associated integrins α2β1 lead to attenuated spheroid 
disaggregation on artificial ECM since primary EOC cells adhere preferentially to type I 
collagens[54], [62], [67]. Furthermore, Davidson et al. showed high expression of αv and β1 integrin 
subunits in malignant cells from peritoneal and pleural effusions collected from late-stage EOC 
patients suggesting a potential role in metastasis[68]. The interaction between vascular cell 
adhesion molecule 1 (VCAM-1) present on the mesothelium and α4β1 integrins on EOC cells 
promotes metastasis and cell migration in xenograft models[69]. Indeed, this study also 
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demonstrated that the use of function-blocking antibodies against either VCAM-1 or α4β1 integrins 
show promise in decreasing EOC metastasis[69]. 
Recent studies suggest that EOC cells may not adhere directly to mesothelial cells, but rather 
to underlying connective tissue; this is achieved by disrupting cell-cell junctions, a process called 
mesothelial cell clearance[70]. Iwanicki et al. demonstrated that EOC spheroids use integrin- and 
talin-dependent activation of myosin traction force to promote mesothelial cell clearance[70]. In 
this experimental model, mesothelial cell monolayers were plated on fibronectin-coated 
polyacrylamide gels to mimic physiologically-relevant stiffness of connective tissue. They showed 
that OVCA433 spheroids induced mesothelial clearance by the above mechanisms[70]. As 
spheroids promote mesothelial clearance, fibronectin fibrils organized on top of mesothelial cells 
are redistributed away from between the mesothelium and attaching spheroids[70]. Blocking of α5 
integrin, talin 1 and non-muscle myosin II abrogated mesothelial displacement, while ectopic 
expression of α5 integrin increased myosin-mediated cell spreading, stress fibers, and other cortical 
actin contractile structures[70]. Collagen I-associated α2 integrin subunit induced fibril 
reorganization and transmitted traction forces to ECM, but spheroids expressing high levels of α2 
integrin rather than α5 integrin were unable to clear the mesothelium[70]. Interestingly, blockade 
of another fibronectin receptor αvβ3 integrins did not affect mesothelial clearance, suggesting these 
specific receptors do not have a myosin-contractility roles in EOC metastasis[70]. In a different 
study, Kokenyesi et al. reported SKOV3 and OVCAR3 cells were unable to invade a collagen I 
matrix due to their inability to disrupt intracellular interactions, highlighting the importance of 
integrin-mediated actomyosin contraction to overcome cell-cell attachments[71].  
A critical component of tumor invasion is enzymatic degradation of the ECM, which permits 
cancer cells to penetrate the basement membrane, gain access to the vasculature and successful 
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formation of secondary tumor growth[40]. Spheroid cell migration using OVCAR5 cells on 
laminin and collagen IV-coated surfaces showed a modest 2-fold change in cell migration over 24 
hours, whereas spheroids on fibronectin and collagen I completely disaggregated to form a 
monolayer with a 9-fold change in surface area[40], [61]. Addition of an inhibitory antibody 
against β1 integrin completely eliminated spheroid cell migration on laminin, fibronectin and type-
IV collagen, and a 50% reduction on type-I collagen[40], [61]. However, these results suggest that 
β1 integrin blockade did not prevent initial spheroid attachment, but rather significantly impacted 
ECM degradation and spheroid disaggregation of invading foci[40]. Overall, β1 integrins partially 
mediate adhesion of EOC spheroid cells to ECM, but likely plays a more significant role in its 
degradation and resultant spheroid disaggregation[40], [61]. 
MMPs are zinc-dependent proteinases that degrade various ECM components, such as 
collagens, proteoglycans, gelatins, vitronectin, and fibronectin[72]. EOC cells that express higher 
levels of MMP2 and MMP9 possess increased invasive and metastatic potential[67], [73]. Studies 
by Kenny et al. demonstrated that contact of EOC cells with mesothelium induces MMP2 
expression at the transcriptional and translational levels[74]. Activated MMP2 cleaves various 
ECM components, including vitronectin and fibronectin, into smaller fragments to improve EOC 
cell adhesion to αvβ3 and α5β1integrin receptors[74]. αvβ3 and α5β1 blocking antibodies inhibited 
cell adhesion, however, this effect was abolished when EOC cells were preincubated with MMP2 
antibody[74].  
When cells migrate away from the core of an attached spheroid, cell-cell contacts are reduced 
while adhesion and spreading on ECM occurs[67]. Compared to monolayer culture, MMP2 and 
MMP9 activities are increased in serum-free medium collected from spheroid culture[67]. 
Increased α2 integrin and decreased α6 integrin subunits in OVHS1 and HEY spheroids were also 
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observed[67]. Interestingly, Shield et al. demonstrated OVHS1 and HEY spheroids have reduced 
disaggregation in the presence of α2, β1 and α2β1 integrin with a coordinated reduction in active 
MMP2 levels[67].  
Furthermore, expression of αvβ6 in EOC is correlated with increased expression and secretion 
of high molecular weight-urokinase-type plasminogen activator (uPA), pro-MMP2 and pro-
MMP9, in tumor-conditioned media[73]. Interestingly, αvβ6 integrin expression is restricted to 
metastatic EOC cells with little to no expression in benign and normal ovarian epithelial cells[75]. 
Ahmed et al. suggest that αvβ6 integrin-expressing EOC cell lines have an enhanced capacity to 
degrade the basement membrane in a plasminogen-dependent manner since this effect was 
completely abolished by inhibition of uPA, MMP9, and αvβ6 integrins[73]. 
 
1.5. Integrins as therapeutic targets for EOC  
Novel therapies that focus on malignant cells and the tumor microenvironment in EOC have 
gained substantial interest due to the heterogeneity of the disease. As described in detail above, 
integrins are key regulators at various steps in the unique metastatic cascade of this disease, 
particularly in spheroid formation, and for peritoneal invasion where integrin-ECM interactions 
are essential for initiating spheroid adhesion[36]. Insight into the cellular mechanisms involved in 
cancer cell survival and progression over the last decade have led to the development of integrin 
inhibitors[13]. Preclinical and clinical studies of integrin antagonists show promising results in 
effectively blocking tumor progression[76].  
Integrin inhibitors represent a feasible therapeutic strategy since the majority of Phase I 
clinical trials demonstrate that these agents are well-tolerated by patients in conjunction with 
cytotoxic chemotherapy or radiotherapy[13], [36]. The chimeric monoclonal antibody 
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Volociximab targets α5β1 integrin and has been successful in inhibiting angiogenesis and 
impairment of tumor growth[77]. Preclinical data shows that intraperitoneal treatment of 
SKOV3ip1 xenografted mice with Volociximab reduced tumor burden and ascites accumulation 
by 83% and 97%, respectively[77]. Encouragingly, clinical trials showed that EOC patients with 
platinum-resistant disease treated with a weekly administration of Volociximab was well 
tolerated[78]. ATN-161 is a non-RGD based synthetic pentapeptide derived from fibronectin that 
binds to and blocks both α5β1 and αvβ3 integrins[79]. This agent has shown promise using mouse 
xenograft models of breast cancer metastasis and it was safe in patients with stable disease in Phase 
I trials, but has not been tested in EOC patients yet[80], [81]. Etaracizumab is an anti-human 
monoclonal antibody against αvβ3 developed after encouraging preclinical results showing 
decreased tumor burden in SKOV3ip1 and HEYA8 xenograft mouse models[82]. However, 
clinical trials showed minimal effectiveness as a therapeutic treatment for metastatic disease[79]. 
Another humanized antibody Intetumumab targeting αvβ3 and αvβ5 showed effective inhibition of 
cancer cell adhesion and migration of six different uterine serous papillary carcinoma cell lines in 
vitro[83]. Phase I clinical trials show that it is safe, it localized to tumors, and shows signs of 
potential anti-tumor activity, but these early findings require additional trials[84]. Although 
promising results have been seen with anti-integrin αvβ3 antibodies, results from Kaur et al. suggest 
that of αvβ3 overexpression in fact correlates with favorable patient outcome; thus, further clinical 
investigations are required[65]. 
Although approaches for targeting integrins may offer therapeutic potential in the future, no 
single integrin receptor complex inhibition strategy has shown sufficient clinical trials results to 
progress for further investigation yet[36]. One major hurdle impeding success may be the 
complexity and dynamics of integrin functions implicated in EOC tumor growth and metastasis 
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(Figure 1.2). For instance, the crucial interaction of EOC cells for adhesion via fibronectin is not 
limited to α5β1 integrin, as αvβ3 or α3β1 integrins can compensate for loss of function[36]. Adding 
to this challenge will be the broad intratumor and interpatient heterogeneity in this disease. Taken 
together, we foresee that a combined approach of targeting multiple integrin-associated pathways 















A schematic model of ovarian cancer dissemination and the role of integrins in cancer metastasis. The primary site of 
origin for HGSOC is the secretory epithelial cells of the distal fallopian tube from precursor STIC lesions and the 
increase in L1CAM and increased ligation of fibronectin to α5β1 promotes cell detachment. Detached EOC cells 
survive in hypoxic and anchorage-independent conditions by forming heterogenous multicellular structures known as 
spheroids to avoid anoikis. Spheroid formation can be enhanced with the interaction of integrins with various ECM 
proteins. Integrins such as α2β1  and α3β1  clustering leads to the loosening of intercellular adhesions between cells and 
contributes to EMT-MET switching. The final step of EOC metastasis occurs when spheroids penetrate mesothelial 
surfaces, and integrin-mediated degradation of the ECM within the basement membrane underlying the peritoneum 





1.6. The role of β5 Integrin in cancer pathogenesis  
Integrin β5 (ITGβ5) encodes for an integrin subunit that interacts with the integrin αv  to 
form a functional transmembrane heterodimer[13]. It is present on the surface of several cancer 
subtypes and interacts with ligands with the arginine-glycine-aspartate (RGD) sequence 
motif[13, 92]. Although no selective ligand has been identified for integrin 𝛽5, it is less 
promiscuous than other integrins and binds preferentially to vitronectin and most small 
molecules that bind to the heterodimer αvβ3 [93, 94]. Previous studies have shown that integrin 
β5 is a prognostic bio-marker within various malignancies including human pancreatic, breast, 
gastric and ovarian cancers [95–98].  Although, a new study aimed to explore the prognostic 
values of the integrin superfamily in HGSOC using The Cancer Genome Atlas (TCGA) and 
GSE9891dataset found that Integrin β5 was significantly downregulated in HGSOC compared to 
control groups [92].  
There has been accumulating evidence of β5 integrin facilitating cell survival, 
angiogenesis, cancer cell migration, invasion and transforming growth factor β (TGF- β) induced 
EMT [58, 100, 101]. Hood et al. show that αvβ5 and αvβ3 contribute to sustained Ras-extracellular 
signal-related kinase (Ras-ERK) signaling in blood vessels, which is a requirement for 
endothelial cell survival and angiogenesis [93]. In Glioblastoma, integrin β5  overexpression is 
not only associated with poor patient survival but also promotes migration and invasion in 
glioma cells [94]. Furthermore, there is evidence that integrin β5 plays a role in carcinoma cell 
motility through the binding of PAK4, a p21-activated group II kinase, to the cytoplasmic 
domain of integrin β5 [95]. The group show that the engagement of integrin β5 and vitronectin 
led to the redistribution of PAK4 from cytosol to colocalization with integrin β5 and ultimately 
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human breast carcinoma cell migration [95]. The depletion of integrin β5 in triple-negative breast 
carcinoma cells reduces the tumor take, growth and angiogenesis, whereas the re-expression of 
integrin β5 can rescue this phenotype [89]. Bianchi et al. revealed that integrin β5 mediates Src-
FAK and MEK-ERK signaling events and inhibition of these pathways produces the same 
phenotype as integrin β5 deficiency [89]. Interestingly, integrin β5 is associated with enhanced 
cell glycolysis to promote cancer cell growth and proliferation and counteracting cisplatin 
cytotoxicity in breast and cervical cancer cells [96]. Wang et al. demonstrated that Src-induced 
phosphorylation of FAK at Tyr861 was involved in integrin β5-mediated glycolysis, further 
expanding the different functions of integrin β5—FAK signaling [96].  
TGF-β signaling is critical for various functions such as apoptosis, cell proliferation, 
differentiation, adhesion, tumor progression and the promotion of EMT [104–107]. Using 
mRNA sequencing data and clinical prognostic information of hepatocellular cancer patients 
from TCGA database, integrin β5 was identified as EMT associated gene and part of a 5-gene 
prognostic risk model for patients [101]. In colorectal cancer, Shi et al. show that higher integrin 
β5 expression is associated with EMT process and TGF- β signal activation [102]. When integrin 
β5  was silenced, the EMT process was attenuated because there was reduced Smad 
phosphorylation by the decrease in Snail1, Twist1 and TGFβ1 [102]. These results suggest that 
the upregulation of integrin β5 may possibly enhance TGF-β signaling and the EMT process, 
thereby promoting tumor growth and metastasis in colorectal cancer [102]. These findings are 
consistent with previous reports that show the loss of integrin β5hinders breast carcinoma cell 
growth, tumor angiogenesis and migration by inhibiting Src/FAK and MEK/ERK signaling [89]. 
Bianchi et al. highlights the upregulation of integrin β5 during TGF-β induced EMT in breast 
carcinoma that requires the Smad transcription factors [58]. The depletion of integrin β5 
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significantly reduced the invasiveness of breast carcinoma cells, blocked the TGF-β induced 
EMT and therefore impairing adhesion to cell-matrix and integrin signaling [58]. Although it has 
been shown that intact TGF-β signaling is critical to control EMT in EOC ascites-derived 
spheroids and promotes the malignant characteristics of these structures, the relationship between 
TGF-β and integrin β5 in ovarian cancer in unclear [57].  
While there is a body of literature that suggests roles of integrin β5 in various 
malignancies, the function of integrin β5 within ovarian cancer is limited. Gillan et al. suggest 
that Periostin (PN), formerly called osteoblast-specific factor-2, is secreted by EOC cells, 
accumulates in the ascites and functions as a ligand for integrins αvβ3 and αvβ5 to promote EOC 
dissemination, cell adhesion and migration [103].  They show that purified recombinant PN 
supports EOC cell adhesion that can be inhibited by a monoclonal antibody against αvβ5 and αvβ3 
but not anti-β1 [103]. Moreover, Maubant et al. derived a cisplatin-resistant cell line, IGROV-
R10, and when grown in monolayer culture, they have an enhanced ability to spontaneously 
release cell clusters with high proliferative abilities [104]. Compared to the parental IGROV1 
cells, IGROV-R10 cells show a strong enrichment of αvβ5 on the surface of monolayer cells as 
well as the spontaneously formed cell clusters in suspension [104]. This highlights the 
chemoresistance associated dysregulation of integrin expression on cell surfaces and is the first 
report to access the altered expression of integrin β5 due to cisplatin resistance [104]. 
Furthermore, integrin β subunit activate a common set of cytoplasmic tyrosine kinases such as 
FAK, a gene that is amplified by 24% in serous ovarian cancer and is associated with decreased 
overall patient survival [76, 112]. Tancioni et al. show that the inhibition of FAK or integrin β5 
knockdown reduce ovarian tumor cell growth under anchorage-independent conditions, which 
corresponds to decreased orthotopic tumor growth [91]. It seems that FAK inhibition disrupts the 
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autocrine or paracrine signaling that regulates integrin β5 in addition to osteopontin levels in 
ovarian carcinoma cells [91].  
 
 
1.7. Role of LKB1-NUAK1 signaling in EOC Tumor Progression  
The revelation of important molecular pathways in spheroid formation would increase 
understanding of metastasis and potentially uncover novel therapeutic targets. Liver Kinase B1 
(LKB1) is encoded by the STK11 gene and is a serine-threonine master kinase[106]. It is widely 
expressed in established ovarian cancer cell lines and patient derived ascites[107]. LKB1 
expression increases in ovarian cancer spheroids compare to monolayer, suggesting an important 
role in spheroid formation [107]. Our group has shown that LKB1 is critical for metastasis and 
the loss of LKB1 can decrease anchorage-independent growth and viability of spheroids[108].  
LKB1 is activated when it forms a complex with accessory proteins STRAD and MO25 [109]. 
LKB1 can then activate downstream target AMP-activated protein kinase (AMPK), which 
regulates metabolic stress through phosphorylation modification of threonine 172 [109]. This 
results in the coordinated downregulation of anabolic pathways and upregulation of catabolic 
pathways in order to create homeostasis [109]. Our group went on to show that LKB1 ablation 
resulted in significantly decrease number of viable cells and increased dead cell count in 
spheroids culture of EOC cell lines tested [108]. This highlights the tumor forming and 
metastatic potential of EOC cells by the loss of LKB1. However, our group has shown that 
LKB1 pro-metastasis role in ovarian cancer occurs through AMPK-independent signaling 
because in spheroids lacking LKB1, p-AMPK levels were maintained [108]. This suggests that 
the ability of LKB1 to regulate 12 other AMPK related kinases may represent other targets by 
which LKB1 maintains spheroid formation and cell viability.   
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One of the top substrate identified by multiplex inhibitor beads-mass spectrometry 
analysis from the loss of LKB1 is NUAK1 [38]. NUAK1 can function in tumor progression 
through regulating apoptosis, invasion and metastasis in tumors [110].  For instance, loss of 
NUAK1 led to a reduction of ATP levels and decreased proliferation in hepatocellular and 
pancreatic carcinoma cells [111]. In ovarian cancer specifically, NUAK1 overexpression has 
been linked to lower progression free survival and lower overall survival [112]. Furthermore, 
there is an increased risk of advanced stage diagnosis and reoccurrence after cytoreduction 
surgery [112]. NUAK1 has increased expression in spheroids compared to monolayer and is 
involved in increasing EOC cell adhesion [38]. By examining NUAK1 Knock out (KO) green 
fluorescent protein (GFP) labeled spheroids, we were able to evaluate spheroid formation. It was 
observed that the loss of NUAK1 creates spheroids that are less compact and with an 
accumulation of dead cells around the periphery [38]. NUAK1 appears to impair single cell 
adhesion and spheroid formation. We postulate that NUAK1 regulates cell adhesion and ECM 
interactions to help form spheroids that spread through the peritoneal cavity. Through Gene Set 
Enrichment analysis (GSEA), the hallmark database revealed multiple cell attachment pathways 
involved in integrin cell attachment that were differentially expressed in NUAK1 knockout 
spheroids [38]. The FN1 gene encoding fibronectin, a known critical ECM protein in EOC 
spheroids, showed a 745-fold decrease in the NUAK1 knockout spheroids [38]. When comparing 
OVCAR8 parental monolayer cells to spheroids, there was an increase in fibronectin expression 
with the presence of multiple isoforms [38]. However, in OVCAR8-NUAK1KO spheroids, there 
was no detectable expression of fibronectin, suggesting NUAK1 may be critically required for 
the expression of fibronectin. Interestingly, when soluble fibronectin was reintroduced 
to NUAK1KO spheroids, native spheroid formation was rescued [38]. Altogether, this revealed a 
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new mechanism through which NUAK1 promotes EOC cell adhesion and spheroid compaction 
through fibronectin matrix production.   
 
 
1.8. Research goal, hypothesis and objectives 
Our previous studies show that the ablation of LKB1-NUAK1 signaling pathway in EOC 
cells resulted in a substantial loss of fibronectin expression leading to spheroid disaggregation 
[38]. Numerous studies have shown that fibronectin binds to its canonical receptor α5β1 in 
ovarian cancer but there was no differential expression of this receptor [6], [41]. Our 
transcriptome analysis demonstrated a coordinated reduction in β5 integrin expression due to 
NUAK1 loss [38] and therefore, I sought to investigate the function of β5 integrin in ovarian 
cancer. I hypothesize that of β5 integrin is required for epithelial ovarian cancer cell adhesion, 
spheroid formation and subsequent spheroid reattachment. To test this hypothesis, I 
characterized the mRNA expression of β5 integrin using publicly-available databases and protein 
expression using western blot analysis of established and patient ascites-derived EOC cell lines. 
Furthermore, I performed siRNA-mediated knockdown in established cell lines in monolayer and 
anchorage independent culture to assess the functional role of β5integrin using cell adhesion, cell 
viability, spheroid viability and reattachment assays. This project has allowed me to elucidate the 
role of β5integrin in ovarian cancer cell adhesion and spheroid reattachment which have not 
previously been explored.  
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2. Materials and Methods 
2.1. Expression Analysis using Publicly Available Datasets 
To obtain the expression level of ITGB5 and ITGB8 we downloaded RNAseq TPM gene 
expression data for protein coding genes RSEM from Depmap (Source: DepMap, Broad (2021): 
DepMap 21Q2 Public. figshare. Dataset. (https://doi.org/10.6084/m9.figshare.14541774.v2). 
Counts are Log2 transformed, using a pseudo-count of 1.  Prior to downstream analysis dataset 
was filtered by removing all samples that were not identified as 'Ovarian Cancer' in 'disease' 
column. RNAseq data was downloaded from cBioportal using all integrin gene names as query 
search. The provisional ovarian serous carcinoma dataset for solid tumour data (n=606) was used 
and the 47 ovarian cancer cell lines from the Cancer Cell Line Encyclopedia data was used.   
 
2.2. Cell culture and treatments 
OVCAR3, OVCAR5, OVCAR8, CAOV3, HEYA8, COV362, OVCA 420 and OVCA 433 cells 
were cultured in RPMI-1640 (Wisent, St. Bruno, QC). FT190, TOV21G, ES-2, 105C, KOC7C, 
OVTOKO, OVMANA, SMOV2, and the patient ascites-derived (iOvCa) cells were cultured in 
DMEM-F12 (Life Technologies). For all cell lines growth medium was supplemented with 10% 
FBS (Wisent, St. Bruno, QC). OVCAR3, OVCAR5, OVCAR8, CAOV3, HEYA8 cells were 
obtained from ATCC. COV362 cells were received from Z. Khan (University of Western 
Ontario, London, ON). The immortalized human fallopian tube secretory epithelial cell line 
FT190 was provided by R Drapkin (University of Pennsylvania, Philadelphia, PA). The iOvCa 
cell lines were established by Dr. Gabriel DiMattia (University of Western Ontario, London, 
ON) based on a protocol described previously [113]. TOV21G was provided by Dr. Anne-Marie 
Mes-Masson (University of Montréal, Montreal, QC) and ES-2, OVCA 420 and OVCA 433 are 
from Dr. Barbara Vanderhyden (University of Ottawa, Ottawa, ON). The 105C originally 
referred to as SCHM-1 were obtained from Dr. Hal Hirte (McMaster University, Hamilton, ON). 
KOC7C, OVTOKO, OVMANA and SMOV2 were kindly provided by Dr. Hiroaki Itamochi 
(Iwate Medical University, Iwate-ken, Japan).  
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Cells were grown in a humidified incubator at 37°C with 5% CO2. Adherent cells were cultured 
on tissue cultured-treated polystyrene (Sarstedt, Newton, NC). Spheroids were formed by 
culturing cells on ultra-low attachment dishes (Corning, NY) that have a hydrophilic and neutral 
coating to allow for cell clustering as described previously [33].   
 
2.3. Small-interfering RNA Transfection 
Cells were seeded in 6-well dishes and seeding density per well was based on proliferation of 
each cell line. FT190 cells were seeded at a density of 3.0 x 105 cells/well, OVCAR8 1.25 x 105
 
cells/well, HEYA8 1.5 x 105 cells/well, TOV21G 2.0 x 105 cells/well, and ES-2 1.0 x 105
 
cells/well. After 24 hours, cells were transfected according to the manufacturer’s protocol 
(Dharmacon, Thermo Fisher Scientific). The combination of 4 μL DharmaFect-1 (T-2001-02) 
with 10 nM of siRNA in 2 ml of media was incubated for 30 minutes. ITGβ5 (L-004125-00-
0005) and non-targeting control pool (D-001206-14-05) siGENOME SMARTpool siRNAs were 
obtained from Dharmacon. The combined siRNA/DharmaFect1 complexes were added to each 
well containing cell and incubated at 37°C with 5% CO2. After 24 hours, the transfection media 
was replaced and 72 hours post transfection, cells were trypsinized and seeded for adherent and 
spheroid culture for experimental conditions. Lysates were also collected 3 days post-
transfection for western blot analysis.  
 
2.4. Immunoblot analysis 
Whole cell lysates from were obtained from 3 days of adherent culture or 3 days post 
transfection. Cells were collected by washing the wells with PBS and scraping cells in lysis 
buffer [50mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 
mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 1 mM PMSF. 1X protease inhibitor cocktail (Roche, Laval, 
QC), and 225mM β-glycerophosphate]. Protein concentration was determined with Bradford 
assay (Bio-Rad Laboratories, Hercules, CA).  
 
Protein samples were prepared using 30 μg of protein determined by Bradford assay and 
resolved by SDS-PAGE using 6% or 8% gels for ~ 2.5 hours. Electrophoresis was followed by a 
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1 hour wet-transfer onto PVDF membrane (Immobilon-P) at 100 V. Membranes were blocked 
for 1 hour with 5% Bovine Serum Albumin (BSA) diluted in TBST (10 mM Tris–HCl, pH 8.0, 
150 mM NaCl and 0.1% Tween-20). Primary antibody against ITGβ5 (1:1000 dilution in 5% 
BSA, Cell signaling #3629), Tubulin (1:20 000 dilution in 5% BSA, Sigma T5168) and Vinculin 
(1:20 000 dilution in 5% BSA, Sigma V9264) was left on membranes overnight at 4°C. Next 
day, membranes were washed 3x with TBST for a total for 45 minutes. Membranes were then 
incubated for 1 hour with peroxidase-conjugated anti-rabbit (1:10 000 dilution in 5% BSA, 
Sigma NA934V) or anti-mouse (1:10 000 dilution in 5% BSA, Sigma NA931V) antibodies and 
washed 3x for 45 minutes with TBST. The membranes were then incubated with Immobilon 
Classico Western HRP Substrate (Millipore Sigma (Oakville, ON) for 5 minutes and images 
were captured using the ChemiDoc™ Imaging system (Bio-Rad) and bands were quantified 
using Image Lab 4.1 software.  
 
2.5. Flow Cytometry 
Three days following siRNA transfection, cells were detached using 0.53mM EDTA (Wisent 
Bioproducts 325-060-EL) and placed in the incubator at 37°C with 5% C02 for 10 minutes, cells 
were mechanically dislodged with a P200 pipette and incubated again for 10 minutes. Once cells 
are dissociated, 2 mL of FACS Buffer (5% FBS diluted in PBS) was added and cells were 
counted (TC10 cell counter, Bio-Rad) to ensure 5 x105 cells were transferred to 1.5 mL 
Eppendorf tubes. Samples were centrifuged at 2000rpm for 5 minutes and washed with 150 μL 
FACS Buffer. After 2-3x washes and centrifuged, 200 μL of FACS Buffer was added and 
incubated with primary AlexaFluor488 αvβ5  anti-human/rat (5 μL, Biolegend) antibody for 1 
hour. Samples were washed 2-3x with FACS Buffer and on the last wash, add 50 μL with 
fixation Buffer (2% paraformaldehyde diluted in PBS) for 20 minutes. After the samples were 
centrifuged, 200 μL of FACS Buffer was added and samples were incubated overnight at 4°C. 
Next day, samples were centrifuged and washed 2-3x and 500 μL volumes were strained and 
transferred over to flow tubes. Samples were analyzed using an EPICS XL-MCL or Cytomics 





2.6. Timed Cell Adhesion Assay 
Cells were seeded in a 24-well standard tissue culture-treated dish at 200 000 cells per well. At 
specific time points determined from previous experiments (Collins & Shepherd, unpublished) 
(45 minutes for HEYA8 cells, 4 hours for OVCAR8 cells, 1 hour for FT190, TOV21G and ES-2 
cells), non-adherent cells were aspirated, the plate was washed with PBS, then trypsinized and 
counted with Trypan Blue to quantify single cell adhesion. Time points were determined using a 
time course cell adhesion assay, where single cell adhesion was quantified using Trypan Blue for 
all 5 cell lines without transfection. The time points used were: 30 min, 45 min, 1 hour, 2 hours, 
3 hours, 4 hours, 5 hours and 6 hours. Cells were counted using TC10 cell counter (Bio-Rad) and 
values were normalized to the initial seeding density. The time point at which all cells have 
attached was used as the time point comparing siNT and siITGβ5 conditions for each cell line. 
 
2.7. Determination of Doubling Time 
Three days after siRNA transfection cells were seeded in a 48-well adherent culture at a density 
of 7500 cells per well. (Essen Bioscience, Ann Arbor, MI), Percent confluence was measured by 
Incucyte for 7 days by capturing phase contrast images every 3 hours and taking the average of 9 
images. To calculate doubling time, an exponential growth curve was fitted to the confluence-
over-time results in Graphpad PRISM.  
 
2.8. Trypan Blue Exclusion Viability Assay 
Three days following siRNA transfection cells were seeded in a 24-well standard tissue culture -
treated plate at a density of 125 000 cells per well or ultra-low attachment (ULA) plates at a 
density of 50 000 cells per well for 24 or 72 hours. Adherent cells were detached using 50 μL 
trypsin-EDTA (0.25%) and incubated at 37°C with 5% CO2 for 10 minutes. After adding 100 μL 
of FBS, cells were transferred to 1.5 mL Eppendorf tubes and 150 μL of Trypan Blue dye 
(ThermoFischer Scientific) was added to each tube. Stained cells were added to the cell counter 
slide and viability readings were taken using TC10 cell counter (Bio-Rad).  
Spheroids from 24-well ULA plates were transferred to 1.5mL Eppendorf tubes and centrifuged 
at 1500rpm for 3 minutes. Media was completely aspirated from tubes avoiding the pelleted 
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spheroids at the bottom. Pellets were washed twice with 1mL of PBS, centrifuged again and 
media was aspirated. A volume of 50 μL of trypsin-EDTA (0.25%) was added and tubes were 
placed in 37°C water bath for 30 minutes with gentle vortex every 10 minutes. After incubation, 
100 μL FBS was added to resuspend the dissociated spheroids followed by resuspending in 150 
μL of Trypan Blue dye (ThermoFischer Scientific). Once cells were counted using TC10 cell 
counter, the total cell number and live cell number were recorded.  
2.9. CellTiter-Glo Spheroid Viability assay 
Three days after siRNA transfection cells were seeded in 96-well ULA plate at a seeding density 
of 4000 cells per well for 24 or 72 hours. CellTiter-Glo® reagent (Promega) was added to each 
well at a volume of 100 μL (1:1 ratio of CellTiter-Glo® reagent and Media in the well). Three 
wells for each time point consisted of only media and the CellTiter-Glo® reagent at a 1:1 ratio 
(Blank controls). Plates were incubated overnight at -80°C to ensure lysis. The following day 
198 μL was transferred from each well into a white-walled 96-well plate. Readings were 
measured on Wallac 1420 victor 2 spectrophotometer plate reader, measuring luminescence. The 
average luminescence readings for Blank control wells (i.e., media alone) were subtracted from 
the luminescence readings from the average per experimental condition. 
 
2.10. Spheroid Reattachment Assays 
Three days following siRNA transfection cells were seeded in 96-well ULA plates at a seeding 
density of 4000 cells per well for 24 or 72 hours. The cultured spheroids were then transferred to 
48-well adherent culture plates with 1 mL of 10% FBS media and incubated at 37°C with 5% 
CO2. Spheroids were permitted to reattach and disperse for an additional 24 hours prior to fixing 
and staining using HEMA3 (Fisher, Kalamazoo, MI, USA). Spheroid reattachment and 
dispersion areas were calculated using the Trainable Weka segmentation analysis plugin on the 
Fiji Image J 2.1 software (NIH). Total spheroid reattachment for full wells was quantified by 
creating classifiers that can differentiate between the background well and the stained area of the 
reattached spheroid. Once the program has differentiated the image using the classifiers, a black 
and white binary image was created in order for the program to calculate the total area for the 
regions of interest. Spheroid dispersion area was calculated using the same Trainable Weka 
segmentation analysis plugin on the Fiji Image J 2.1 software (NIH) using high magnification 
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images. Classifiers were used to differentiate between the background and the stained spheroid 
area and a binary image was created to calculate the total spheroid reattachment area for single 
spheroids. This process was repeated using 3 different classifiers to differentiate between 
spheroid core, dispersing monolayer and well background area and calculate the area for the 
reattached spheroid core. Spheroid dispersion was defined as the spheroid core area subtracted 
from the total reattached spheroid area for OVCAR8, TOV21G and ES-2. Due to the 
morphology of the spheroids of FT190 and HEYA8, this method could not be used. Instead, total 
reattached spheroid area was quantified alone. 
 
Spheroid reattachment assays with the ECM-coated plates were completed with spheroids 
cultured in 96-well ULA plates at a seeding density of 4000 cells per well for 24 hours.  
Spheroids were then transferred to either BSA, fibronectin or vitronectin coated 24-well adherent 
culture plates with 1 mL of 0% FBS media and incubated at 37°C with 5% CO2. The fibronectin-
coated plates were acquired from Corning Life sciences and stored at 4°C until use. The 
vitronectin-coated plates were prepared using human recombinant vitronectin (Millipore Sigma, 
SRP3186) as per the manufacturer’s guidelines. The BSA-coated plates were prepared by 0.1% 
BSA diluted in sterile water. Spheroids were permitted to reattach and disperse for an additional 
24 hours prior to fixing and staining using HEMA3. Spheroid reattachment and single spheroid 
areas were calculated using the Trainable Weka segmentation analysis plugin on the Fiji Image J 
2.1 software (NIH).  
 
2.11. Statistical Analysis 
Statistical analysis was completed using Graphpad PRISM 9 (GraphPad Software, San Diego, 
CA). Analyses were performed using two-tailed Student’s t-test and a p-value less than 0.05 was 
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3. Results  
3.1. Integrin gene expression in serous ovarian tumours and ovarian 
cancer cell lines 
To begin, mRNA expression levels of all integrins were evaluated using publicly available 
datasets from the from the Cancer Genome Atlas (TCGA). By assessing the expression of the 
superfamily of integrins among ovarian cancer tumors and cell lines, we can then evaluate the 
expression of integrin β5 within this framework. The data suggests that there is wide variability in 
expression of both integrin 𝛼- and β-subunits (Figure 3.1). Interestingly, the expression of 
integrin 5 is high relative to other β-subunits in both serous ovarian tumours and cell lines. 
Integrin 5 mRNA expression is the third highest β-subunit in the tumours (Figure 3.1A) and 
second highest in gene expression among ovarian cancer cell lines (Figure 3.1B). Furthermore, 
the 𝛼-subunit associated with integrin 5 to form a functional heterodimer, integrin 𝛼𝑣 also has 
relatively high expression and is the second highest 𝛼-subunit expressed in both serous ovarian 
tumors (Figure 3.1A) and ovarian cancer cell lines (Figure 3.1B).  
 
3.2. Integrin β5 is expressed across established ovarian cancer cell lines and 
patient-ascites derived cell lines 
To further validate the data from TCGA, we sought to evaluate the expression of integrin 5 
within well-established cell lines across two subtypes of ovarian cancer: High-grade serous 
ovarian cancer cell lines (HGSOC) and clear cell carcinoma cell lines (OCCC). HGSOC is the 
most common and most aggressive subtype accounting for 75% of all EOCs [8]. Although early 
detection of OCCC has a patient 5-year disease-free survival rate of 86-89%, advanced stage 
prognosis is remarkably poorer than that of patients with serous carcinoma [114]. The use of 
readily available and well-established cell lines from both subtypes provides appropriate context 
for assessing the role of integrin 5 in EOC. Transcript expression data for HGSOC and OCCC 
was obtained from the Cancer cell line encyclopedia (CCLE) dataset and the protein expression 
was evaluated using western blot analysis with adherent culture day 3 lysates.  
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The mRNA expression of integrin 5 is expressed with high variability across multiple HGSOC 
and clear cell carcinoma cell lines (Figure 3.2A).  When assessing the protein level expression 
of integrin 5, it was evident that integrin 5 expression varies across both ovarian cancer 
subtypes but is still detectable (Figure 3.2B, 3.2C). The clear cell carcinoma cell lines that have 
shown the highest integrin β5 protein expression level were OVMANA and KOC7C whereas, 
the SMOV2, TOV21G, ES-2 and 105C show similar yet lower levels (Figure 3.2B, 3.2C). The 
HGSOC cell lines that show the highest integrin β5 protein expression are the OVCA 420, 
OVCA 433 and OVCAR5 cell lines (Figure 3.2B, 3.2C). The CAOV3, HEYA8 and OVCAR8 
cell lines show similar integrin 5 protein expression to the normal fallopian tube immortalized 
control cell line, FT190 (Figure 3.2B, 3.2C). The immortalized fallopian tube cell line is used as 
a control since it is now widely considered that HGSOC initiates from the secretory epithelial 
cells of the distal fallopian tube [26]. The HGSOC cell lines that show very little integrin 5 
protein expression are the OVCAR8 and COV362 (Figure 3.2B, 3.2C).  
Several early-passage ovarian cancer patient-ascites derived cell lines generated by our 
laboratory (G. DiMattia) were also used to evaluate the protein expression of integrin 5 through 
western blot analysis. Similar to the established cell lines, the patient-ascites derived cell lines 
exhibit detectable integrin 5 protein expression (Figure 3.2D, 3.2E). This overall assessment of 
integrin β5 expression among established cell lines enabled us to identify appropriate cell lines 
for functional assays using targeted siRNA-mediated knockdown. The cell lines chosen display a 
spectrum of integrin β5 expression to account for the differences across cell lines when 
evaluating the function of integrin β5 within EOC (Table 3.1).  
3.3. Transient Knockdown of Integrin 5  leads to a decrease in cell 
viability of EOC cells in adherent culture 
To evaluate the role of integrin 5 within EOC, siRNA-mediated knockdown of ITGβ5 in 
OVCAR8, HEYA8, TOV21G and ES-2 cell lines was completed (Figure 3.3). OVCAR8 and 
HEYA8 are well established HGSOC cell lines and TOV21G and ES-2 are representative OCCC 
cell lines. Based on the previous western blot analysis, HEYA8 have higher protein expression of 
integrin 5 than OVCAR8 (Figure 3.2B, 3.2C). Whereas, both TOV21G and ES-2 show similar 
protein level expression of integrin β5 (Figure 3.2B, 3.2C). Transient knockdown was also 




Figure 3.1: Integrin 5 has relatively high expression across serous ovarian tumors and cancer cell lines 
(A) Integrin family gene expression in serous ovarian tumors and ovarian cancer cell lines (B) obtained from 
publicly-available The cancer genome atlas (TCGA) dataset. Integrin 𝛼𝑣 has the second highest alpha subunit gene 
expression in ovarian tumors and cancer cell lines. The shading represents the subclasses of I-domain and non-




Figure 3.2: Integrin 5 transcript and protein expression is detectable across two EOC subtypes and patient 
ascites derived cell lines 
(A) Transcript expression (transcript per million) was obtained from Cancer Cell line encyclopedia (CCLE) dataset 
for clear cell carcinoma and HGSOC cell lines. (B) Representative western blots of integrin β5 protein expression 
across both clear cell carcinoma and HGSOC cell lines. The results are presented as the mean±SD. (n=3) (C) 
Densitometry analysis shows pixel intensity volume for integrin β5 relative to vinculin across both clear cell 
carcinoma and HGSOC cell lines. (D) Representative western blot of integrin β5 across patient ascites derived 
iOVCA cell lines. (E) Densitometry analysis shows pixel intensity volume for integrin β5 relative to tubulin. The 




Table 3.1 Summarya of Epithelial ovarian cancer cell lines 
Cell line EOC subtype Mutations Integrin Interaction 
FT190 Immortalized normal 
distal fallopian tube 
-- Increased L1CAM expression leads to 
increased spheroid formation due to the 
upregulation of integrin subunits 𝛼5 and 𝛽1 [3] 





Increased L1CAM expression leads to 
increased spheroid formation due to the 
upregulation of integrin subunits 𝛼5 and 𝛽1 [3] 
HEYA8 High grade ovarian 
serous adenocarcinoma 
BRAF, KRAS Treating with integrin subunit 𝛽1 blocking 
antibody MAB13 leads to spheroid 
disaggregation [4] 
Increased 𝛼2 and decreased 𝛼6 integrin subunit 
expression was observed in spheroids [5] 
The use of anti-αvβ3 Etaracizumab leads to 
decreased tumor burden in xenograft mouse 
model [6] 










a Data presented in table obtained for Cancer cell line encyclopedia (CCLE) dataset for 







ITGβ5 was initially validated through western blot analysis using an antibody against integrin β5 
(Figure 3.3A). As a method of additional validation, flow cytometry using an antibody for the 
heterodimer αv5 was performed which shows that knocking down ITGβ5 leads to an 80-85% 
decrease in the expression of the functional heterodimer (Figure 3.3B, 3.3C). Our results suggest 
FT190, HEYA8, ES-2 and TOV21G have a higher level of knockdown than OVCAR8 (Figure 
3.3B, 3.3C). This could be attributed to the already low expression of integrin β5 in the 
OVCAR8 (Figure 3.2B, 3.2C).   
Cell viability assays were completed to assess the viability of knockdown in adherent conditions. 
To evaluate the viability of cells, Trypan blue exclusion counting was conducted at both 24 and 
72 hours. The results indicate that ITGβ5 knockdown significantly decreased the number of 
viable cells in adherent culture for FT190 at 24 hours and OVCAR8 cells at both 24 and 72 hours 
(Figure 3.3D, 3.3E). Although no significant difference in viability is detected in OCCC cell 
lines TOV21G and ES-2 at 24 hours, there is a significant decrease in cell viability at 72 hours 
(Figure 3.3D, 3.3E). Interestingly, the HEYA8 cells showed no significant difference in relative 
cell viability at 24 hours but by 72 hours, there was a significant increase in the number of viable 
cells (Figure 3.3D, 3.3E). Altogether, it seems that the loss of integrin β5 impacts cell viability in 
adherent culture as early as 24 hours in culture.  
 
3.4. Integrin β5 knockdown decreases cell adhesion in EOC without 
altering cell proliferation 
Integrins pose as critical regulators of cancer cell adhesion therefore we sought to evaluate the 
role of integrin β5 as a cell adhesion receptor in EOC. Cell adhesion assay was quantified in 
adherent culture at an appropriate time as determined by time course analysis for each cell line. 
Single cell adhesion was quantified using Trypan blue cell counting. The loss of integrin β5 in 
FT190, OVCAR8 and TOV21G shows a significant decrease in the ability of these cells to attach 
to standard tissue culture-treated substratum (Figure 3.4A, 3.4B). Interestingly, integrin 5 
knockdown appeared to promote OVCAR8 cells to form spontaneous cell clusters rather than 
adhere to the tissue culture plastic. This phenotype was also evident in the other HGSOC cell 
line, HEYA8 but to a lesser degree. There is no significant change in the ability of HEYA8 and 
ES-2 cells to attach when ITGβ5 is knocked down (Figure 3.4A, 3.4B). To assess whether the 
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altered adhesion affects proliferation rate, cell doubling time analyses were completed. The 
results indicate that there is no significant change in doubling times between the control and 
knockdown conditions among all cell lines (Figure 3.4C). Overall, the results suggest that the 
knockdown of ITGβ5 decreases the cell adhesion of FTE cells and the majority of EOC cell 
lines.  
 
3.5. Transient knockdown of Integrin β5 impacts spheroid viability 
As a next step, it was important to evaluate β5 integrin function in anchorage-independent 
conditions since this is a critical step in EOC metastasis. After siRNA-mediated knockdown of 
ITGβ5, spheroid viability analysis was performed by Trypan blue exclusion cell counting using a 
TC10 automated cell counter. The loss of integrin β5 does not result in any overt change in spheroid 
phenotype compared to control (Figure 3.5A). Although there is so significant change in spheroid 
viability from integrin 5 knockdown in normal FT190 cells at 24 hours, there is a significant loss 
of viable cells by 72 hours in suspension culture (Figure 3.5B, 3.5C). OVCAR8 cells exhibited a 
decrease in spheroid viability at 24 hours from the loss of integrin β5, however, this decrease is not 
sustained at 72 hours (Figure 3.5B, 3.5C). Similarly, ES-2 cells have a significant decrease in 
spheroid viability at 24 hours and continue to have a decreased trend in the number of viable cells 
at 72 hours (Figure 3.5B, 3.5C). Interestingly, there is a significant increase in the number of 
viable HEYA8 cells at 72 hours and TOV21G cells in spheroid culture at both 24 and 72 hours 
(Figure 3.5B, 3.5C). CellTiter-Glo Luminescence cell viability assay was used as an additional 
method to assess spheroid cell viability based upon ATP as an indicator of metabolically-active 
viable cells. As indicated by previous spheroid viability results, ITGβ5 knockdown results in a 
significant increase in the average luminescence in TOV21G cells (Figure 3.5D). However, all 
other cells lines showed no difference in spheroid cell viability based on CellTiter-Glo assay 







Figure 3.3: Transient knockdown of integrin 5 leads to a decrease in cell viability of EOC cells in adherent 
culture 
(A) Immunoblot analysis validating ITGβ5 knockdown in FT190, OVCAR8, HEYA8 TOV21G, ES-2. Tubulin is 
used as a loading control. (B) Flow cytometry analysis of the ITGβ5 knockdown in FT190, OVCAR8, TOV21G and 
ES-2 cells transfected with control siNT or siITGβ5 using αvβ5-antibody. (C) The average αvβ5 fluorescence of cells 
was calculated. The results are presented as the mean±SD. Analysis was performed using two-tailed student’s t-test 
(****, P < 0.0001; ***, P < 0.001) (n=3). (D) Cell viability for FT190, OVCAR8, HEYA8, TOV21G and ES-2 
siNT and siITGβ5. Viable cell number was determined by Trypan blue exclusion cell counting at 24 and (E) 72 
hours in adherent culture. Data is presented as viable cell number normalized to their respective controls. Analysis 
was performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05;**, P < 0.01; ***, P < 0.001) .  
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Figure 3.4: Integrin β5 knockdown decreases cell adhesion in EOC without altering cell proliferation 
(A) Images of FT190, OVCAR8, HEYA8, TOV21G, ES-2 siNT control and siITGβ5 cultured for 24 hours in 
adherent culture plates. Scale bars 200 μm. Images were captured using Leica light microscope (n=3). (B) Single 
cell adhesion was quantified with Trypan blue cell counting for FT190, OVCAR8, HEYA8, TOV21G and ES-2 si 
ITGβ5 and matched controls. Analysis was performed using two-tailed student’s t-test (*, P < 0.05) (n=3). (C) 
Doubling time for FT190, OVCAR8, HEYA8, TOV21G and ES-2 cells transfected with siNT or siITGβ5. Incucyte 
Zoom Imaging system measured percent confluence over 7 days. Graphpad PISM was used to generate growth 
curves and non-linear regression analysis calculated doubling time. (NS= not significant). (n=3). Graphpad PRISM 
















Figure 3.5: Transient knockdown of integrin 5 impacts spheroid viability 
(A) Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 in spheroid culture for 24 hours. 
Scale bars 500 μm. Images were captured using Leica light microscope (n=3) (B) Spheroid viability for FT190, 
OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5. Viable cell number was determined by Trypan blue 
exclusion cell counting at 24 hours and (C) 72 hours. Data is presented as viable cell number normalized to their 
respective controls. Analysis was performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05; ;**, P 
< 0.01;***, P < 0.001) (n=3). (D) Spheroid viability for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and 
siITGβ5. Average luminescence was determined by CellTiter-Glo assay 24 and 72 hours after transfection. Data is 
presented as absolute viable cell number. The results are presented as the mean±SD. (*, P < 0.05) (n=3) 
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3.6. Loss of integrin β5 decreases spheroid reattachment in OVCAR8 
spheroids and impacts subsequent cell spreading in multiple EOC 
cells 
To evaluate the role of integrin 5 in a model of secondary metastasis, cell lines that were 
transfected with either control or siITGβ5 were seeded to form spheroids. Spheroids were collected 
at 24 and 72 hours to perform re-attachment to tissue culture-treated plates. The loss of integrin 5 
results in no significant difference in relative spheroid reattachment for FT190, HEYA8, TOV21G, 
and ES-2 spheroids at both 24 (Figure 3.6A, 3.6B) and 72 hours (Figure 3.6A, 3.6C). Although 
there is a decreasing trend of spheroid reattachment in TOV21G and ES-22, there is an increasing 
trend in spheroid reattachment in HEYA8 spheroids at both time points (Figure 3.6B, 3.6C). 
Surprisingly, OVCAR8 cells show a dramatic decrease in the ability of spheroids to reattach at 
both 24 and 72 hours due to ITGβ5 knockdown (Figure 3.6A, 3.6B, 3.6C).  
 
In addition to quantifying total spheroid reattachment within an entire well, we investigated the 
change in spheroid area for individual reattached spheroids. Dispersion area was calculated by 
subtracting the spheroid core area from the total spheroid area as determine using Image J FIJI 
segmentation plugin. However, FT190 and HEYA8 spheroids do not have a measurable spheroid 
core so it was not possible to calculate dispersion area using this method (Figure 3.6D). For these 
two cell lines, the quantification for single spheroids is shown as total reattached spheroid area. 
The FT190 reattached spheroids show no difference in spheroid area at 24 hours (Figure 3.6D, 
3.6E), but there is a significant decrease in spheroid area at 72 hours in the ITGβ5 knockdown 
condition (Figure 3.6D, 3.6F). At 24 hours, both OVCAR8 and ES-2 show a significantly 
decreased ability of cells to disperse from the spheroid core once attached to tissue culture-treated 
substratum (Figure 3.6D, 3.6E). Although OVCAR8 spheroids are larger is size after 72 hours of 
spheroid culture, the altered ability of cells to disperse is still evident due to the loss of integrin 5 
(Figure 3.6D, 3.6F). Although there was no significant difference in dispersion area for TOV21G 
reattached spheroids at both time points and for ES-2 at 72 hours, there was a change in spheroid 
morphology (Figure 3.6D, 3.6E, 3.6F). Interestingly, HEYA8 reattached spheroids have a 
significantly larger spheroid area when integrin 5 is knocked down at both 24 and 72 hours 
(Figure 3.6D, 3.6E, 3.6F). The loss of integrin 5 within the HEYA8 spheroids, exhibited a similar 
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change in cell phenotype as seen with TOV21G and ES-2 in addition to an intensive spheroid core 
(Figure 3.6D).  
 
3.7. Decrease in spheroid reattachment and cell spreading in OVCAR8 
spheroids associated with integrin 5 and vitronectin interaction 
A critical step in secondary tumor formation is the integrin-mediated binding of EOC cells to 
mesothelial cells and the underlying ECM. We assessed the interaction of integrin 5, and its 
associated αv integrin subunit capable of binding with RGD associated ECM ligands fibronectin 
and vitronectin [15], while bovine serum albumin (BSA) was used as a negative control. Similar 
to previous spheroid reattachment assay, spheroids for each cell line were cultured in ultra-low 
attachment plates for 24 hours transferred spheroids to ECM-coated adherent culture plates for 
24 hours. The results indicate that knocking down ITGβ5 does not impact spheroid reattachment 
to either the negative control or fibronectin for FT190 (Figure 3.6A), OVCAR8 (Figure 3.6B), 
HEYA8 (Figure 3.6C) and TOV21G (Figure 3.6D). The results did indicate a significant 
decrease in the ability of OVCAR8 spheroids to reattach in vitronectin-coated wells when ITGβ5 
is knocked down (Figure 3.6B). However, this change due to ITGβ5 knockdown in spheroid 
reattachment with vitronectin was not evident in FT190 (Figure 3.6A), HEYA8 (Figure 3.6C) 
and TOV21G (Figure 3.6D). These results indicate that integrin 5 may play a role in spheroid 
reattachment when interacting with vitronectin in OVCAR8 cells.  
To investigate the change in subsequent cell spreading after spheroid reattachment seen in 
previous spheroid reattachment experiment, we assessed the interaction of integrin 5 with ECM 
ligands fibronectin, vitronectin and BSA. There was no significant difference in subsequent cell 
spreading in FT190 (Figure 3.8A), HEYA8 (Figure 3.8C), TOV21G (Figure 3.8D) spheroids 
when adhering to BSA, fibronectin and vitronectin coated wells. Interestingly, loss of integrin 5 
resulted in more dense reattached HEYA8 spheroids under both fibronectin and vitronectin 
conditions (Figure 3.8C). The results did indicate a dramatic decrease in the ability of OVCAR8 
cells to spread from the reattached spheroid core when the wells were coated with vitronectin 









Figure 3.6: Loss of integrin 5 decreases spheroid reattachment in OVCAR8 and impacts subsequent cell 
spreading in multiple EOC cells  
(A) Spheroid reattachment Hema-3 stained Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and 
siITGβ5 in spheroid culture for 24 and 72 hours. Images were captured using Axio zoom microscope 9.8x (n=3) (B) 
Relative spheroid reattachment total area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT 
and siITGβ5 at 24 hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as 
total stained area and normalized to their respective controls. Analysis was performed using two-tailed student’s t-
test (NS= not significant;*, P < 0.05). The results are presented as the mean±SD. (n=3). (C) Relative spheroid 
reattachment total area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 at 72 
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area 
and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test (NS= not 
significant;**, P < 0.01). The results are presented as the mean±SD. (n=3). (D) High magnification spheroid 
reattachment Hema-3 stained Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 in 
spheroid culture for 24 and 72 hours. Scale bar FT190 and OVCAR8 200 μm. Scale bar HEYA8, TOV21G and ES-
2 500 μm. Images were captured using Leica light microscope (n=3). (E) Relative spheroid dispersion area 
quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 at 24 hours. FT190 and 
HEYA8 spheroid area was determined by quantifying total area of the reattached spheroid. Dispersion area was 
determined by subtracting spheroid core area from the total area of the spheroid using Image J Segmentation Plugin 
analysis. Data is presented normalized to their respective controls. Analysis was performed using two-tailed 
student’s t-test (NS= not significant;*, P < 0.05; ;**, P < 0.01). The results are presented as the mean±SD. (n=3). 
(F) Relative spheroid dispersion area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and 
siITGβ5 6 at 72 hours. FT190 and HEYA8 spheroid area was determined by quantifying total area of the reattached 
spheroid. Dispersion area was determined by subtracting spheroid core area from the total area of the spheroid using 
Image J Segmentation Plugin analysis. Data is presented normalized to their respective controls. Analysis was 
performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05). The results are presented as the 




















Figure 3.7: Decrease in spheroid reattachment in OVCAR8 spheroids associated with integrin 5 and 
vitronectin interaction 
(A) Spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 using either Bovine Serum Albumin 
(BSA), fibronectin or vitronectin coated adherent tissue culture plates at 24 hours. Images were captured using Axio 
zoom microscope at 6.6x. Relative spheroid reattachment total area quantification for FT190 siNT and siITGβ5 at 24 
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area 
and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test. The results are 
presented as the mean±SD. (n=3). (B) Spheroid reattachment Hema-3 stained Images of OVCAR8 siNT and 
siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue culture plates at 24 hours. Images were 
captured using Axio zoom microscope at 6.6x. Relative spheroid reattachment total area quantification for OVCAR8 
siNT and siITGβ5 at 24 hours. Total area was determined by Image J Segmentation Plugin analysis. Data is 
presented as total stained area and normalized to their respective controls. Analysis was performed using two-tailed 
student’s t-test (*, P < 0.05). The results are presented as the mean±SD. (n=3). (C) Spheroid reattachment Hema-3 
stained Images of HEYA8 siNT and siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue 
culture plates at 24 hours. Images were captured using Axio zoom microscope at 6.6x. Relative spheroid 
reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area was determined by 
Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to their respective 
controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). 
(D) Spheroid reattachment Hema-3 stained Images of TOV21G siNT and siITGβ5 using either BSA, fibronectin or 
vitronectin coated adherent tissue culture plates at 24 hours. Images were captured using Axio zoom microscope at 
6.6x. Relative spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area 
was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to 
their respective controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the 























Figure 3.8: Decrease in subsequent cell spreading after reattachment in OVCAR8 spheroids is associated with 
integrin 5 and vitronectin interaction 
(A) High magnification spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 on BSA, 
fibronectin, and vitronectin coated plates for 24 hours. Scale bar 500 μm. Images were captured using Leica light 
microscope (n=3). Absolute spheroid area quantification for FT190 siNT and siITGβ5 at 24 hours. Total area was 
determined by Image J Segmentation Plugin analysis. Data is presented as total reattached spheroid area. Analysis 
was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). (B) High 
magnification spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 on BSA, fibronectin, and 
vitronectin coated plates for 24 hours. Scale bar 500 μm. Images were captured using Leica light microscope (n=3). 
Absolute spheroid area quantification for FT190 siNT and siITGβ5 at 24 hours. Total area was determined by Image 
J Segmentation Plugin analysis. Data is presented as total reattached spheroid area. Analysis was performed using 
two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). (C) Spheroid reattachment Hema-3 
stained Images of HEYA8 siNT and siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue 
culture plates at 24 hours. Scale bar 500 μm. Images were captured using Leica light microscope (n=3). Relative 
spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area was determined 
by Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to their respective 
controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). 
(D) Spheroid reattachment Hema-3 stained Images of TOV21G siNT and siITGβ5 using either BSA, fibronectin or 
vitronectin coated adherent tissue culture plates at 24 hours. Scale bar 500 μm. Images were captured using Leica 
light microscope (n=3). Relative spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total reattached 
spheroid area and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test. 
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4.1. Summary of findings 
My thesis provides insight into the previously unknown role of integrin 5 in EOC. We have 
shown that integrin 5 mRNA expression is detectable across serous ovarian tumours and cell 
lines. The protein expression of integrin 5 varies across numerous well-established cell lines and 
patient-ascites derived cell lines. Previously, Kaplan-Meier analysis has shown that elevated 
integrin 5 levels in ovarian cancer are significantly associated with decreased patient survival 
and increased immunohistochemistry staining of integrin 5 in advanced stages II-IV compared 
to normal ovary tissue and stage I serous tumors [91]. My transient knockdown data indicates 
that there is a decrease in cell viability within adherent culture across multiple EOC cell lines. 
Alongside the change in viable cell number, there was a significant decrease in the ability of 
cells to adhere to tissue culture substratum. The results indicate that there is no change in 
proliferation rate for all cell lines evident through the doubling time analysis. When studying 
spheroids derived from EOC cell lines, we show that there is no visible change in spheroid 
morphology when integrin 5 is knocked down. Although our results indicate a decrease in 
spheroid viability in three of the five cell lines, there is also a significant increase in the number 
of viable cells in the other two cell lines. To further explore the role of integrin 5 in EOC, we 
evaluated the role of integrin 5 in spheroid reattachment. The results indicate that the ability of 
OVCAR8 spheroids to reattach and cell dispersion is significantly decreased. Alternatively, there 
is an increase in the dispersion area of HEYA8 spheroids although there was no change in the 
ability of these spheroids to reattach. Perhaps spheroid viability contributes to the ability of 
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spheroids to reattach and then disperse. Spheroid viability data suggests that knockdown of 
integrin 5 leads to decreased OVCAR8 spheroid viability whereas, HEYA8 spheroids have 
increased viability.  Lastly, we investigated the role of integrin 5 in integrin-mediated EOC 
spheroid reattachment to various ECM ligands. The results demonstrate that the decrease in 
OVCAR8 spheroid reattachment and subsequent cell spreading is associated with integrin 5—
vitronectin interaction.  
4.2. Integrin 5 knockdown decreases cell adhesion in EOC  
Cell adhesion interactions are involved in numerous physiological processes such as wound 
healing and embryonic development as well as the progression of diseases such as cancer [115]. 
One of the best characterized cell adhesion receptors are integrins, which can play a critical role 
in cell-cell or cell-matrix interactions [3, 4] . Integrins can assemble various forms of cell-matrix 
adhesion such as clustering in focal adhesions and the formation of a mechanical link between 
ECM and intracellular actin bundles [3, 4]. The physical interaction link between cells and ECM 
proteins are the reason integrins are considered mechanosensing receptors [118].  The first step 
of mechanosensing is the conformation change of integrins by moving from a low to high 
affinity conformation through outside-in or inside-out signaling to form integrin clusters on the 
membrane [118]. Previously, it has been demonstrated there is an enrichment of integrin 5 to 
specific adhesion structures during interphase when analyzing cell cycle stages [119]. In our 
study, we showed that the transient knockdown of integrin 5 leads to a significant decrease in 
the ability of FT190, OVCAR8 and TOV21G cells to attach to tissue substratum. These results 
may reflect on the change in signal transductions from the loss of integrin 5 and disruption of 
cell adhesion interactions.  
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One aspect of cell detachment is facilitated by integrin-mediated upregulation of MMPs 
and activation of EMT [36]. For instance, the clustering of α2β1  and α3β1 enables the induction 
of MMP9 that leads to E-cadherin cleavage and cell-cell adhesion loosening through an Src 
kinase-dependent manner [54]. Increased MMP9 expression in ovarian tumor tissues and ascites 
has been associated with disease reoccurrence and poor patient survival [120]. Src family kinases 
are involved in integrin-mediated signal transmission from the extracellular environment via 
FAK activation [121] or through  integrin cytoplasmic tail that can induce Src activation [122]. 
Current data has shown that inhibition of Src activity can block integrin-induced E-cadherin 
ovarian cancer cell dissociation [54]. Furthermore, the loss of cell adhesion to the substratum has 
been defined as anoikis, a form of cell death [123]. However, the use of an αv integrin blocking 
antibody was not associated with cell death despite the alteration of cell adhesion [45]. The 
inhibition of αv integrins resulted in detachment of IGROV1 cells from the substratum and 
altered SKOV-3 cell spreading [45]. There was also a decrease in cell growth and cell cycle 
progression from the αv integrin blockade [45]. This was associated with an inhibition of ILK 
activity and subsequent inhibition of PKB/Akt phosphorylation on serine-473 and upregulation 
of p27Kip1 [45]. Interestingly, our results differed regarding cell growth since we have shown that 
there is no significant change in doubling time across all five cell lines. This difference could be 
attributed to the fact that Cruet-Hennequart et al. measured proliferation by counting cells after a 
48 hour treatment with αv integrin blocking antibody [45] whereas we calculated doubling time 
by measuring percent confluency over a 7 day period post transfection. Furthermore, our study 
focuses on knocking down only one of the αv integrins and so perhaps the loss of multiple αv 
integrins leads to an additive effect and the loss of only integrin 5 could be compensated by 
other αv integrins. Although there was a similar phenotype of cell detachment seen from the loss 
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of integrin 5 in OVCAR8 in adherent culture, this phenotype was not further investigated. 
Therefore, it may be worth further exploration to evaluate the altered cell adhesion interactions.   
4.3. Loss of Integrin 5 decreases spheroid reattachment in OVCAR8 
spheroid and impacts subsequent cell spreading in multiple EOC cells 
EOC metastasis occurs through multicellular disaggregates, known as spheroids, which 
exfoliate from the primary tumor and can reattach at another location within the peritoneum or 
omentum to form a secondary tumor [5]. This form of metastasis suggests that cell-cell and cell-
matrix mechanisms regulate EOC progression and therefore it is critical to understand the 
interactions leading to spheroid reattachment and invasion of the mesothelium [5]. Our results 
indicate that the transient knockdown of integrin 5 leads to a dramatic decrease in spheroid 
reattachment and subsequent spheroid disaggregation on the cell culture plate substratum. 
Although, there was no significant change in spheroid reattachment among the other cell lines, 
there was also a decrease in single spheroid reattachment area with the FT190 at 72 hours. 
However, there was a significant increase in the spheroid dispersion area for the HEYA8 
spheroids when integrin 5 was knocked down. One aspect of the decrease in spheroid 
reattachment and subsequent spheroid reattachment could be attributed to the decrease in 
spheroid viability due to loss of integrin 5 for the OVCAR8 and FT190 spheroids. Interestingly, 
HEYA8 spheroids have shown an increase in spheroid viability and spheroid disaggregation post 
reattachment. These results could suggest that changes in spheroid viability may contribute to 
spheroid reattachment. 
  Furthermore, the previous literature highlights the importance of EMT and change in the 
expression of various integrins could lead to changes in spheroid reattachment. For instance, the 
loss of E-cadherin leads to transcriptional upregulation of fibronectin and α5β1 integrin, which is 
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essential when spheroids initiate adhesion at a secondary site [53]. Interestingly, Bianchi et al.  
have demonstrated that the β-subunits associated with 𝛼𝑣 integrins are upregulated during TGF-β 
induced EMT in breast carcinoma [58]. Specifically, knockdown of integrin 5 blocks the EMT 
response to TGF-β which impairs the assembly of tight junctions and formation of cell-matrix 
adhesion structures in mouse and human mammary epithelial cell lines [58]. This suggests that 
integrin 5 cell-matrix adhesion interactions play a role in EMT process in response to TGF-β 
and the tumorigenic potential of carcinoma cells [58]. We have previously established that TGF-
β activity is induced during ascites-derived EOC spheroid formation indicated by the 
upregulation of Snai1, Twist1, Twist2 and Zeb2 mesenchymal markers [57]. When spheroids 
were treated with either TGF-β receptor 1 inhibitor or DMSO control, there was reduced cell-cell 
cohesion within spheroids and a decrease in spheroid dispersion area [57]. The enhanced 
epithelial phenotype of dispersing cells treated with TGF-β inhibitor compared to the control 
may have contributed to the decrease in cell motility after reattachment. Similar to breast 
carcinoma [58], it may be possible that the regulation of integrin 5 expression and TGF-β 
induced EMT in EOC may impact spheroid reattachment and subsequent cell spreading. Since 
our previous work has shown the role of TGF-β activity in EOC spheroid formation and 
reattachment, it is important that future studies focus on elucidating a possible association of 
integrin 5 and TGF-β induced EMT.  
4.4. Decrease in spheroid reattachment and disaggregation in OVCAR8 
spheroids associated with Integrin 5 and vitronectin interaction  
A critical step in secondary tumor formation is the integrin-mediated binding of EOC 
cells to the underlying ECM of the mesothelial layer. Many studies have shown that integrin 1 
is a critical beta subunit since it can pair with a variety of alpha subunits and participate in EOC 
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cell attachment and migration on ECM substrata relevant to peritoneal metastasis [5]. This 
association has been seen in gastric cancer cells as well, where peritoneal invasion was inhibited 
by blocking integrin α21 association with collagen I and discouraging cancer cell attachment 
[124]. Our results indicate that knocking down integrin 5 results in a significant decrease in the 
ability of OVCAR8 spheroids to reattach and disaggregate on vitronectin-coated substrata. 
However, there was no significant difference in OVCAR8 spheroid reattachment to fibronectin 
or BSA. Although this potential role of integrin 5 has not been seen in EOC previously, the 
inhibition of other integrins has been associated with altered spheroid disaggregation. The 
inhibition of collagen-associated integrin α21 lead to attenuated spheroid disaggregation on 
artificial ECM [8,19, 20]. Burleson et al. have also shown that integrin 1 partially mediates 
adhesion of EOC spheroids to ECM and plays a more significant role in spheroid disaggregation 
[61]. When evaluating spheroid disaggregation on ECM-coated surfaces, the addition of an 
inhibitory antibody against integrin 1, eliminated OVCAR5 spheroid disaggregation on laminin, 
fibronectin and type-IV collagen to an extent and a 50% reduction on collagen I [61]. Although 
our results also indicated a significant decrease in the ability of OVCAR8 spheroids to reattach 
to a vitronectin-coated surface, integrin 1 blockade did not prevent initial spheroid reattachment 
[61]. 
Interestingly, the loss of integrin 5 did not prevent spheroid reattachment or 
disaggregation in the other EOC cell lines. It is known that integrins can play different roles in 
cell fate decisions. For instance, two gastric adenocarcinoma sublines differ in their response to 
anchorange-independent culture where one results in apoptosis and the other results in cell cycle 
arrest [125]. Our results indicate that inhibiting the interaction between integrin 5 and 
vitronectin impacts spheroid reattachment and disaggregation in the OVCAR8 but does not seem 
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to affect the other cell lines. Perhaps this can be attributed to the varying expression of other αv 
integrins across these cell lines. For instance, it may be possible that another αv integrin capable 
of binding with vitronectin is compensating for the loss of integrin 5 and is able to engage in 
signaling pathways allowing for continued spheroid reattachment and subsequent cell spreading. 
Kligys et al. have shown that α6β4 is a master regulator of transcription and translation of other 
integrin subunits and the loss of this heterodimer can decrease the expression of α2 and α3 
integrin subunits [126]. They provide evidence that the α6β4 integrin-dependent signaling via 
phosphorylation of 4EBP1 and activation of PI3K regulates the translation of other integrin 
subunits such as α3 [126]. While αv integrins also interact with vitronectin as an ECM ligand, it 
does not imply that the cell-matrix adhesions will lead similar changes in cell motility. The 
difference in cell migration between two ECM-binding integrin can involve different signaling 
and/or adaptor proteins interacting with differing amino acid sequences on the cytoplasmic tails 
of integrin subunits [127]. In this study, we have knocked down integrin 5, however other beta 
subunits that bind with αv integrin can differ in their cytoplasmic tail and recruit varying adaptor 
proteins forming a different signaling platform [127]. Overall, altering the expression of integrins 
and their composition of cell-matrix adhesion complexes may be a driving force in cancer 
progression processes.  
 
4.5. Limitations of current study 
My work helped to begin the process of uncovering the function of integrin 5 in EOC, 
however there are some aspects of the study that have limitations. This can be explored and 
addressed further through additional experimentation.  
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Firstly, the single cell adhesion assays in adherent culture showed that some cell lines, the 
loss of integrin 5 led to the formation of spontaneous cell clusters that were suspended in the 
media. Previous literature has shown that these cell clusters can form by budding directly from a 
monolayer where budding was associated with vertical growth, continued cell-cell interactions 
and eventual release of the cell cluster [34]. Pease et al. reveal that the cell lines capable of 
forming these cell clusters in adherent culture showed a lack of E-cadherin at cell-cell borders 
and the presence of vimentin filaments throughout the cytoplasm through immunofluorescence, 
indicating the cells have undergone EMT [34]. To evaluate the altered cell adhesion properties 
between the cells in monolayer and the cell clusters in the media, it may be helpful to collect the 
supernatant with the cell clusters separate monolayer to perform microarray analysis. This may 
provide insight into changes in gene expression from the transient knockdown of integrin 5 
between the cell clusters and monolayer. Furthermore, comparing the supernatant lysates with 
the monolayer using western blot analysis to probe for EMT associated proteins may provide 
advantageous in further evaluating the role of integrin 5 and cell adhesion interactions.  
In addition, the spheroid reattachment experiments provided valuable insight into the 
function of integrin 5 in secondary metastasis and the interaction with ECM proteins. Our study 
shows that the interaction between integrin 5 and vitronectin is important for OVCAR8 
spheroid reattachment and subsequent cell spreading. However, there are multiple aspects of 
secondary metastasis that ultimately reinforce locally invasive behaviour of EOC such as, ECM 
stiffness that increases integrin signaling and subsequent activation of associated pathways [128]. 
A study by McKenzie et al. investigated the tumor microenvironment that regulates EOC 
morphology, migration and spheroid disaggregation using polymer hydrogels with elastic 
properties that mimic those of the peritoneum [128]. The peritoneum represents a major target 
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for EOC dissemination and polyacrylamide hydrogels that were fabricated with physiologically 
appropriate ECM stiffness serve as experimentally relevant adhesive substrates [128]. These gels 
can then be coated with different ECM proteins and can help to evaluate EOC cell size, actin 
cytoskeletal organization and focal adhesion morphology through immunofluorescence [128]. 
Moreover, this method provides a physiologically relevant model of the peritoneum to evaluate 
spheroid reattachment and disaggregation. Alternatively, Kenney et al. have established a 3D 
model of the key components of the omental microenvironment, mesothelial cells, fibroblasts 
and ECM, to study ovarian cancer cell adhesion and invasion [129]. They provide evidence that 
omental mesothelial cells inhibit, while omental fibroblasts and underlying ECM enhance the 
attachment and invasion of EOC cells [129]. The use of this model provides the ability to study 
EOC spheroid attachment and disaggregation in the context of the microenvironment which is 
critical in EOC metastasis.  
Furthermore, it is critical to understand integrin crosstalk and the diverse number of 
compensatory mechanisms involved. Our work focuses on investigating the function of integrin 
5 and we have assessed this through siRNA-mediated knockdown. However, this integrin 
subunit is only one of another 7 beta subunits and 18 alpha subunits. Integrins possess an innate 
characteristic where the change in the expression of integrin subunits or the activation of certain 
integrins can interfere with the expression or activation of another [130]. For instance, the 
expression of integrin α3 decreases the activation of αv, while inhibiting integrin α3 leads to the 
activation of αvβ3 expression in several cancer cell types [131]. Furthermore, in the melanoma 
cell line MDA-MB-435S which expresses integrins 3 and 5, the knockdown of 3 or 5, 
upregulates αvβ5 and αvβ3 respectively [132]. Therefore, western blot analysis to explore whether 
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other αv integrins are engaging in compensation mechanisms when integrin 5 is knocked down 
may provide insight into the different phenotypes observed across the cell lines.  
Lastly, spheroid formation and subsequent reattachment is an essential step in EOC 
metastatic cascade. To mimic spheroid formation and subsequent reattachment in this study, a 
3D spheroid culture model was used to form spheroids in ULA. These spheroids were then 
reattached in adherent culture plates to mimic secondary tumor formation. When completing 
these experiments, the spheroids were reattached in media contained FBS. For in vitro cell 
expansion, ECM components of FBS as well as other materials of animal origin are required for 
cell culture [31]. The use of 10% FBS when completing the spheroid reattachment assays is a 
limitation of the experiment since the ECM components within the media can coat the plastic 
surface of the well and play a role on cell adhesion. In the future, the use of cell culture media 
without FBS in spheroid reattachment assays can address this restriction. This limitation was 
addressed going forward in the spheroid reattachment assays with ECM-coated wells where the 
spheroids were reattached in media with no FBS.  
 
4.6. Overall Conclusions 
My work has contributed to the growing literature evaluated the role of the integrin 
family in cancer progression. I have shown that integrin 5 may play a role in EOC and 
knockdown of this beta subunit decreases cell adhesion across multiple cell lines. Furthermore, 
the results indicate that the loss of integrin 5 has a dramatic impact on spheroid reattachment 
subsequent cell spreading in the OVCAR8 cell line. OVCAR8 is a HGSOC cell line that has 
rapid tumor formation ability and for intraperitoneal injections in a xenograft mouse model, 
100% tumor take has been seen [32]. Compared to the other OVCAR cell lines, OVCAR8 is the 
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only one that can reliably form ascites in a xenograft mouse model within 90 days [32]. 
OVCAR8 also forms the largest intraperitoneal tumors (1004-1509 mg) by 27 days [32]. 
Functional characterization in vitro showed that OVCAR8 has the most mesenchymal phenotype 
compared to other HGSOC cell lines such as OVCAR5, OVSAHO, SNU119 and CAOV3 [32]. 
Although, we have gained new insights into the influence of integrin 5 in the context of 
EOC, it is vital to continue further experimentation of the results prior to making final 
conclusions. My results elucidate that complexity of integrin-mediated cell adhesion interactions 
in EOC, since the phenotypes differ across the different cell lines evaluated. By uncovering the 
expression of other integrin heterodimers and possible integrin cross talk, future studies may 
provide insight into the diversity of integrin function among EOC tumors. Integrins are key 
regulators at various steps in the EOC metastatic cascade; therefore, if we can continue to 
elucidate potential integrin-mediating signaling mechanisms, it can potentially address the 
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